Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4395089 and Mirikizumab in Crohn's Disease
NCT07483099Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of LY4395089 in Crohn's disease, sponsored by Eli Lilly and Company. Started May 2026; status: recruiting.
02
Drugs
LY4395089
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07483099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07483099.